Research / ACNT / Fundamental state Inspectable configuration
State dimensions Filing 0000095953-26-000109 General Corporate
Capex intensity 95th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.capex_revenue_ratio
2.94% · OPTIONAL · VALID
Operating cash generation 5th Own-history percentile · N=20
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-8.95% · OPTIONAL · VALID
Revenue growth 85th Own-history percentile · N=20
Evidence method Yoy · gp.fundamentals.revenue
37.61% · CORE · VALID
Inventory pressure 40th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.inventory_revenue_ratio
40.86% · OPTIONAL · VALID
Gross margin 85th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.gross_margin
21.62% · CORE · VALID
Operating margin 55th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.operating_margin
-1.02% · CORE · VALID
R&D intensity RAW Current state valid · history insufficient
Evidence method Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
0.42% · OPTIONAL · NOT_ENOUGH_HISTORY
SBC intensity 90th Own-history percentile · N=20
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
0.81% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 33 states Self-history eligible
Sep 30, 2021 8/8 normalized Level 3 Dec 31, 2021 8/8 normalized Level 3 Mar 31, 2022 8/8 normalized Level 3 Jun 30, 2022 8/8 normalized Level 3 Sep 30, 2022 8/8 normalized Level 3 Dec 31, 2022 8/8 normalized Level 3 Mar 31, 2023 8/8 normalized Level 3 Jun 30, 2023 8/8 normalized Level 3 Sep 30, 2023 8/8 normalized Level 3 Dec 31, 2023 8/8 normalized Level 3 Mar 31, 2024 7/7 normalized Level 3 Jun 30, 2024 7/7 normalized Level 3 Sep 30, 2024 7/7 normalized Level 3 Dec 31, 2024 8/8 normalized Level 3 Mar 31, 2025 7/7 normalized Level 3 Jun 30, 2025 7/7 normalized Level 3 Sep 30, 2025 7/7 normalized Level 3 Dec 31, 2025 7/8 normalized Level 3 Mar 31, 2026 7/8 normalized Level 3 Jun 30, 2026 7/8 normalized Level 4 Period transition
What moved in the state? Capex Intensity Increased
Previous 2.17%
Current 2.94%
Delta 0.76% Cash Generation Increased
Previous -27.96%
Current -8.95%
Delta 19.01% Growth Increased
Previous -21.50%
Current 37.61%
Delta 59.11% Inventory Pressure Increased
Previous 38.26%
Current 40.86%
Delta 2.60% Margin Increased
Previous 14.48%
Current 21.62%
Delta 7.14% Profitability Increased
Previous -12.24%
Current -1.02%
Delta 11.22% R And D Intensity Increased
Previous 0.32%
Current 0.42%
Delta 0.09% Sbc Intensity Increased
Previous 0.81%
Current 0.81%
Delta 0.01% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Mar 31, 2026
Similarity 76%
Compared 7 dimensions
Coverage 100% Growth 35.0 · Margin 35.0 · Profitability 40.0 · Sbc Intensity 0.0 · Capex Intensity 0.0 · Cash Generation 5.0 · Inventory Pressure 5.0 Mar 31, 2025
Similarity 71%
Compared 7 dimensions
Coverage 100% Growth 65.0 · Margin 5.0 · Profitability 15.0 · Sbc Intensity 25.0 · Capex Intensity 20.0 · Cash Generation 5.0 · Inventory Pressure 15.0 Sep 30, 2022
Similarity 70%
Compared 7 dimensions
Coverage 100% Growth 23.5 · Margin 37.9 · Profitability 7.9 · Sbc Intensity 19.4 · Capex Intensity 53.8 · Cash Generation 12.6 · Inventory Pressure 30.6 Sep 30, 2025
Similarity 63%
Compared 7 dimensions
Coverage 100% Growth 80.0 · Margin 15.0 · Profitability 10.0 · Sbc Intensity 10.0 · Capex Intensity 5.0 · Cash Generation 50.0 · Inventory Pressure 10.0 Sep 30, 2024
Similarity 62%
Compared 7 dimensions
Coverage 100% Growth 60.0 · Margin 10.0 · Profitability 5.0 · Sbc Intensity 10.0 · Capex Intensity 35.0 · Cash Generation 70.0 · Inventory Pressure 5.0 Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.